New insider activity at Abbott Laboratories ( (ABT) ) has taken place on February 8, 2025.
Chairman & CEO Robert Ford has made a significant transaction by selling 285,388 shares of Abbott Laboratories stock, totaling a value of $37,434,343.
Recent Updates on ABT stock
Over the last 24 hours, Abbott Laboratories has seen positive developments in its stock outlook following its Q4 earnings call. Analysts have raised their price targets for Abbott’s stock, citing strong growth drivers such as the FreeStyle Libre, electrophysiology products, leadless pacemakers, and cardiovascular devices. The company’s ability to develop and launch new products is expected to sustain growth in sales and earnings. Despite facing challenges such as currency headwinds and increased taxes, Abbott’s diverse MedTech portfolio and strategic financial management are viewed as key strengths. The recent earnings report highlighted robust performance in its Medical Devices and adult nutrition segments, as well as record operating cash flow, which is being strategically reinvested. These factors have led to an optimistic outlook for 2025, with expectations of significant organic sales growth and improvement in operating margins.
More about Abbott Laboratories
YTD Price Performance: 13.95%
Average Trading Volume: 5,807,057
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $222.4B